BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32753543)

  • 21. Longitudinal studies of the
    Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiparametric
    Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
    J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
    Ren Y; Pan F; Kan X; Wang J; Han P; Yan J; Li L; Sun P; Liu CY; Bao Q; Yang L; Zheng C
    Mol Pharm; 2022 Oct; 19(10):3664-3672. PubMed ID: 35976154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
    Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
    Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of metabolic response with
    Segreto S; Fonti R; Ottaviano M; Pellegrino S; Pace L; Damiano V; Palmieri G; Del Vecchio S
    Cancer Imaging; 2017 Mar; 17(1):10. PubMed ID: 28264726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission computed tomography and magnetic resonance imaging features of sinonasal small round blue cell tumors.
    Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
    Neuroradiol J; 2020 Feb; 33(1):48-56. PubMed ID: 31460836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
    Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
    J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Value of
    Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
    Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
    Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
    Seith F; Forschner A; Schmidt H; Pfannenberg C; Gückel B; Nikolaou K; la Fougère C; Garbe C; Schwenzer N
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):95-101. PubMed ID: 28831583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI.
    Theruvath AJ; Siedek F; Muehe AM; Garcia-Diaz J; Kirchner J; Martin O; Link MP; Spunt S; Pribnow A; Rosenberg J; Herrmann K; Gatidis S; Schäfer JF; Moseley M; Umutlu L; Daldrup-Link HE
    Radiology; 2020 Jul; 296(1):143-151. PubMed ID: 32368961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
    Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.